RxDoctor Payments Data

Deborah Kirk, MD

Family Medicine · Smyrna, DENPI 1427069475

Payments from drug & device makers

$1,586in general payments, 2019–2025

Across 133 payments — averaging $11.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$814
  • Lilly USA, LLC$182
  • Pfizer$149
  • Novo Nordisk$52
  • Seqirus USA Inc$51
  • AstraZeneca$48
  • plus $291 from 10 others

What the payments were for

  • Food & beverage$1,56699%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,586 in reported general payments places this provider in the 75th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$629,916
Medicare patients
876
Services billed
7,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin93$105,714
TrulicityDulaglutide33$60,596
OzempicSemaglutide34$54,956
EliquisApixaban30$32,189
FarxigaDapagliflozin Propanediol34$27,428
VascepaIcosapent Ethyl23$22,704
XareltoRivaroxaban13$19,542
JanuviaSitagliptin Phosphate11$17,627
Breo ElliptaFluticasone/Vilanterol29$15,972
Diazepam11$14,245
Rosuvastatin Calcium387$12,586
Atorvastatin Calcium290$6,442
SymbicortBudesonide/Formoterol Fumarate11$6,124
Ezetimibe122$5,076
Desvenlafaxine Succinate ErDesvenlafaxine Succinate26$4,148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$15$105,71493 claims
Lilly USA, LLCTrulicity$182$60,59633 claims
Novo NordiskOzempic$52$54,95634 claims
AstraZenecaFarxiga, Symbicort$48$33,55245 claims
PfizerEliquis$149$32,18930 claims
Johnson & JohnsonXarelto$18$19,54213 claims
MerckJanuvia$39$17,62711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 352 family medicine providers in Delaware.

Other family medicine in Smyrna

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →